300587-89-7
300587-89-7
Chemical Structure
UCB1244283
- CAS No.: 300587-89-7
- Formula:C20H25NO2
- Molecular Weight:311.42
InChIKey: XJYBAKSVSQKCNC-UHFFFAOYSA-N
SMILES: O=C(NC1=CC=CC=C1OC)CC(C)CC2=CC(C)=CC(C)=C2
Biological Activity: UCB1244283 is a synaptic vesicle glycoprotein 2A (SV2A) allosteric modulator. UCB1244283 binds to a secondary ligand-binding site in SV2A and enhances orthosteric ligand engagement when the orthosteric site is occupied, by stabilizing the occluded state and slowing ligand dissociation. UCB1244283 shows a clear protective effect against both tonic and clonic convulsions in sound-sensitive mice. UCB1244283 can be used for epilepsy research[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
UCB1244283 | 99.97% | UCB1244283 is a synaptic vesicle glycoprotein 2A (SV2A) allosteric modulator. UCB1244283 binds to a secondary ligand-binding site in SV2A and enhances orthosteric ligand engagement when the orthosteric site is occupied, by stabilizing the occluded state and slowing ligand dissociation. UCB1244283 shows a clear protective effect against both tonic and clonic convulsions in sound-sensitive mice. UCB1244283 can be used for epilepsy research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Pidathala S, et al. Structural pharmacology of SV2A reveals an allosteric modulation mechanism in the major facilitator superfamily. Nat Commun. 2025 Nov 28;16(1):10748. [Content Brief]
- [2]. Wood MD, et al. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia. 2018 Sep;59(9):e147-e151. [Content Brief]
- [3]. Daniels V, et al. Modulation of the conformational state of the SV2A protein by an allosteric mechanism as evidenced by ligand binding assays. Br J Pharmacol. 2013 Jul;169(5):1091-101.
